Cost analysis of kidney transplantation in highly sensitized recipients compared to intermittent maintenance hemodialysis

Ann Transplant. 2012 Dec 31;17(4):82-91. doi: 10.12659/aot.883698.

Abstract

Background: Kidney transplantation in allosensitized recipients has recently increased. Studies performing cost analysis of desensitization protocols are scarce.

Material/methods: We performed an actual cost comparison between kidney transplantation following desensitization and maintenance hemodialysis. Group A (n=35) consisted of allosensitized recipients who underwent desensitization using immunoadsorption and/or plasmapheresis, intravenous immunoglobulin and anti-CD20 antibody who were followed for ≥ 2 years. Group B (n=49) consisted of matched patients who remained on hemodialysis throughout the study period. Actual costs of donor care, surgical procedures, out-patient visits, in-hospital admissions, medications, hemodialysis, immunoadsorption, plasmapheresis, and laboratory and radiology investigations were calculated. Health care services were provided by a single institution.

Results: Mortality rate was similar between both groups. The average 4-year actual total cost was $210,779 in group A and $317,186.3 in group B; respectively (p=0.017). Average total cost per patient in group A was $186,608; $14,233; $5,536; $4,402 in the first, second, third and fourth years after transplantation respectively while the average total annual cost per patient in group B was $79,296. The total cost in both groups became equal by month 31. The predicted annual cost savings in group A after 31 months was $33,943.

Conclusions: Despite using costly desensitization protocols, kidney transplantation in sensitized patients provides long-term cost savings compared to maintenance hemodialysis.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / economics
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Female
  • Follow-Up Studies
  • Graft Enhancement, Immunologic / economics*
  • Graft Enhancement, Immunologic / methods
  • Graft Rejection / prevention & control
  • HLA Antigens / immunology
  • Histocompatibility
  • Hospital Costs / statistics & numerical data*
  • Humans
  • Immunoglobulins, Intravenous / economics
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / economics
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / economics
  • Immunosuppressive Agents / therapeutic use
  • Isoantibodies
  • Kidney Failure, Chronic / economics
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / therapy*
  • Kidney Transplantation / economics*
  • Kidney Transplantation / immunology
  • Kidney Transplantation / mortality
  • Male
  • Middle Aged
  • Renal Dialysis / economics*
  • Renal Dialysis / methods
  • Renal Dialysis / mortality
  • Retrospective Studies
  • Rituximab
  • Saudi Arabia
  • Sorption Detoxification / economics
  • Sorption Detoxification / methods
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • HLA Antigens
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Immunosuppressive Agents
  • Isoantibodies
  • Rituximab